{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T05:39:14Z","timestamp":1751607554935,"version":"3.37.3"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1124\/jpet.122.001555","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T14:50:16Z","timestamp":1682607016000},"page":"164-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiac Monitoring Guidelines in Clinical Trials and Post-Approval Surveillance for Patients Exposed to Anticancer Treatments: Do the Data Support the Recommendations?"],"prefix":"10.1016","volume":"386","author":[{"given":"Michael S.","family":"Ewer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas L.","family":"Palaskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Herson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001555_bib1","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1200\/JCO.2014.58.9465","article-title":"Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older patients with breast cancer","volume":"33","author":"Chavez-MacGregor","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.122.001555_bib2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/FJC.0000000000001216","article-title":"Chemotherapy-induced arrhythmias","volume":"80","author":"Essa","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"year":"2019","series-title":"Cancer and the Heart","author":"Ewer","key":"10.1124\/jpet.122.001555_bib3"},{"key":"10.1124\/jpet.122.001555_bib4","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000495147","article-title":"False positive cardiotoxicity events in cancer-related clinical trials: risks related to imperfect noninvasive parameters","volume":"63","author":"Ewer","year":"2018","journal-title":"Chemotherapy"},{"key":"10.1124\/jpet.122.001555_bib5","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.122.001555_bib6","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1200\/JCO.22.01006","article-title":"Could some reports of trastuzumab cardiotoxicity be a surveillance artifact?","volume":"40","author":"Ewer","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4, Suppl 12","key":"10.1124\/jpet.122.001555_bib7","first-page":"96","article-title":"Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?","volume":"26","author":"Ewer","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1124\/jpet.122.001555_bib8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.hfc.2011.03.001","article-title":"A historical perspective of anthracycline cardiotoxicity","volume":"7","author":"Ewer","year":"2011","journal-title":"Heart Fail Clin"},{"key":"10.1124\/jpet.122.001555_bib9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1161\/01.CIR.102.3.272","article-title":"Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity","volume":"102","author":"Feldman","year":"2000","journal-title":"Circulation"},{"key":"10.1124\/jpet.122.001555_bib10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE-Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr"},{"key":"10.1124\/jpet.122.001555_bib11","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-associated atrial fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1124\/jpet.122.001555_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/lpr\/mgl012","article-title":"Uncertainty, insurance and the Learned Hand formula","volume":"5","author":"Grossman","year":"2006","journal-title":"Law Probab Risk"},{"key":"10.1124\/jpet.122.001555_bib13","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1016\/j.jacc.2021.02.040","article-title":"Gaining efficiency in clinical trials with cardiac biomarkers: JACC review topic of the week","volume":"77","author":"Januzzi","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/jpet.122.001555_bib14","doi-asserted-by":"crossref","first-page":"7954","DOI":"10.1038\/s41598-021-87209-8","article-title":"Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer","volume":"11","author":"Lakhani","year":"2021","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.122.001555_bib15","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.echo.2017.06.025","article-title":"Reliability of left ventricular ejection fraction from three-dimensional echocardiography for cardiotoxicity onset detection in patients with breast cancer","volume":"30","author":"Lorenzini","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1124\/jpet.122.001555_bib24","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1124\/jpet.122.001555_bib16","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/jpet.122.001555_bib17","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1093\/annonc\/mds130","article-title":"Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs","volume":"23","author":"Naing","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1124\/jpet.122.001555_bib18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0025-6196(11)60896-3","article-title":"Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials","volume":"83","author":"Perez","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1124\/jpet.122.001555_bib19","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/annonc\/mdx773","article-title":"Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study","volume":"29","author":"Swain","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1124\/jpet.122.001555_bib20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/jpet.122.001555_bib21","unstructured":"United States v. Carroll Towing Co., Inc. (1947) Circuit Court of Appeals, Second Circuit. 159 F.2d 169."},{"key":"10.1124\/jpet.122.001555_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaccao.2021.01.004","article-title":"Myocarditis surveillance with high-sensitivity troponin i during cancer treatment with immune checkpoint inhibitors","volume":"3","author":"Waliany","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1124\/jpet.122.001555_bib23","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood.V98.2.266","article-title":"Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide","volume":"98","author":"Westervelt","year":"2001","journal-title":"Blood"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524170619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524170619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:29:58Z","timestamp":1739971798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524170619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0022356524170619"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001555","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac Monitoring Guidelines in Clinical Trials and Post-Approval Surveillance for Patients Exposed to Anticancer Treatments: Do the Data Support the Recommendations?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001555","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}